Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit
November 29 2021 - 7:30AM
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development
company focused on DNA-based immunotherapy and next-generation
vaccines, announces that Khursheed Anwer, Ph.D., executive vice
president and chief science officer, will be making a presentation
on the Company’s GEN-1 interleukin 12 (IL-12) immunotherapy program
at the Cytokine-Based Cancer Immunotherapies Summit being held in
Boston on November 30 to December 2, 2021. Dr. Anwer’s
presentation, titled “A Non-Viral Gene Therapy Approach to IL-12
Delivery for The Treatment of Cancer,” will be delivered on
December 2 at 8:10 a.m. Eastern time. The Company was invited to
submit a poster presentation which aligns with Dr. Anwer’s oral
presentation on the GEN-1 IL-12 program. The poster presentation
will contain a subset of his presentation slides. Dr. Anwer will
also be participating in two panel discussions.
In his presentation, Dr. Anwer will be
discussing how local delivery of IL-12 without significant systemic
toxicity is feasible with a non-viral gene therapy approach that
involves administration of an IL-12 plasmid with a synthetic DNA
delivery system (GEN-1). Dr. Anwer will also be discussing how
weekly intraperitoneal administration of GEN-1 yields durable
increases in IL-12 and IFN-, and why repeated weekly
administration of GEN-1 in combination with standard chemotherapy
remodels the tumor immune environment to favor immune stimulation
over immune suppression.
“We are pleased that the Cytokine-Based Cancer
Immunotherapies Summit is recognizing Celsion’s leadership for and
potential efficacy of cytokines as an immunotherapy for the
treatment of serious malignancies,” said Michael H. Tardugno,
chairman, president and chief executive officer of Celsion.
“Results from the Company’s Phase I Study of GEN-1 in advanced
ovarian cancer is attracting the interest of leading researchers in
the field of immunotherapy.”
Dr. Anwer will also participate in two panel
discussions:
- On December 1 at 8:30 a.m. Eastern
time titled, “What Do We Know & Where Do We Want to Go?”
- On December 2 at 11:30 a.m. Eastern
time titled “Side Effects – Mitigating Against Hypotension + Fever
With Immune-Stimulating Agents (NK Cell Engagers, PD-1s, Cytokines,
T-Cell Engagers) = Cytokine Release Syndrome (CRS)?”
About GEN-1 Immunotherapy
GEN-1, designed using Celsion's proprietary
TheraPlas™ platform technology, is an IL-12 DNA plasmid vector
encased in a nanoparticle delivery system that enables cell
transfection followed by persistent, local secretion of the IL-12
protein. IL-12 is one of the most active cytokines for the
induction of potent anticancer immunity acting through the
induction of T-lymphocyte and natural killer (NK) cell
proliferation and maturation. The company previously reported
positive safety and encouraging Phase I results with GEN-1 given as
monotherapy or a combination therapy in patients with advanced
peritoneally metastasized primary or recurrent ovarian cancer, and
recently completed a Phase Ib dose-escalation trial (OVATION 1
Study) of GEN-1 in combination with carboplatin and paclitaxel in
patients with newly diagnosed ovarian cancer. GEN-1 in combination
with neoadjuvant chemotherapy is the subject of the ongoing
randomized Phase II OVATION 2 Study in subjects with advanced-stage
ovarian cancer (Stage III/IV), with enrollment now exceeding 75%
and full enrollment targeted by the first half of 2022.
About Celsion
Corporation
Celsion is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative cancer treatments, including immunotherapies and
DNA-based therapies, and a platform for the development of nucleic
acid vaccines currently focused on SARS-CoV-2. The Company’s
product pipeline includes GEN-1, a DNA-based immunotherapy for the
localized treatment of ovarian cancer. Celsion also has two
feasibility-stage platform technologies for the development of
novel nucleic acid-based immunotherapies and other anticancer DNA
or RNA therapies. Both are novel synthetic, non-viral vectors with
demonstrated capability in nucleic acid cellular transfection. For
more information on Celsion, visit www.celsion.com.
Celsion GmbH is Celsion’s wholly owned, special
purpose subsidiary based in Zug, Switzerland. Celsion GmbH is
responsible for supporting studies of ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, is under
investigator-sponsored development for several cancer indications.
For more information on Celsion GmbH, visit
www.celsiongmbh.com.
Forward-looking Statements
Forward-looking statements in this news release
are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon current beliefs, expectation, and assumptions and
include statements regarding the platform having the potential to
provide broad protection against coronavirus disease 2019
(COVID-19), and possible future mutations of SARS-CoV-2 or other
coronaviruses. These statements are subject to a number of risks
and uncertainties, many of which are difficult to predict,
including the ability of the Company’s platform to provide broad
protection against COVID-19, and possible future mutations of
SARS-CoV-2 or other coronaviruses, the issuance of a patent to the
Company for use of its technology platform for treating or
preventing infection with the SARS-CoV-2 virus that causes
COVID-19, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data, particularly
in small subgroups that are not statistically significant; FDA and
regulatory uncertainties and risks; the significant expense, time
and risk of failure of conducting clinical trials; the need for
Celsion to evaluate its future development plans; possible
acquisitions or licenses of other technologies, assets or
businesses; possible actions by customers, suppliers, competitors
or regulatory authorities; and other risks detailed from time to
time in the Celsion's periodic filings with the Securities and
Exchange Commission. Celsion assumes no obligation to update or
supplement forward-looking statements that become untrue because of
subsequent events, new information or otherwise.
CONTACTS:
Celsion CorporationJeffrey W.
ChurchExecutive Vice President and
CFO609-482-2455jchurch@celsion.com
LHA Investor RelationsKim
Sutton Golodetz 212-838-3777kgolodetz@lhai.com
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2024 to May 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From May 2023 to May 2024